Russian Government Discusses STATE ORDER FOR DEVELOPMENT OF DRUGS FOR RARE DISEASES
21.07.2020
“I suggested at the next meeting of the expert council (parliamentary hearings) to hear the Ministry of Health and the Ministry of Industry on the formation of a centralized long-term state order for the development and production of domestic analogues of drugs for rare diseases,” Ogul said.
According to him, today only 11 out of 34 drugs are produced in Russia, which are used in the treatment of orphan diseases. In addition, out of 28 drugs registered in the Ministry of Health, only 10 are of domestic production. “At the same time, the purchase of drugs abroad, firstly, creates a high burden on the budgetary system (an annual course of treatment of one child with SMA with the drug“ Spinraza ”costs about 50 million rubles), and secondly, it jeopardizes the uninterrupted provision of“ orphan ” patients with the necessary drugs, ”Ogul emphasized.
In turn, the development of domestic analogues of imported drugs will reduce budget expenditures for the treatment of orphan diseases, as well as, over time, create in Russia its own scientific, technical and production base for scientific research, development and introduction of such drugs. “According to the Ministry of Health and the Ministry of Industry and Trade, a number of private pharmaceutical companies are now working to bring domestic analogues of imported drugs for rare diseases to the market. We must understand which of them are created with the help of budget funds, where the state order is used, for which specific drugs. And is it possible to consider the possibility of targeted budgetary financing of scientific developments to create a whole range of domestic drugs for the treatment of rare diseases, ”Ogul said.
According to him, today only 11 out of 34 drugs are produced in Russia, which are used in the treatment of orphan diseases. In addition, out of 28 drugs registered in the Ministry of Health, only 10 are of domestic production. “At the same time, the purchase of drugs abroad, firstly, creates a high burden on the budgetary system (an annual course of treatment of one child with SMA with the drug“ Spinraza ”costs about 50 million rubles), and secondly, it jeopardizes the uninterrupted provision of“ orphan ” patients with the necessary drugs, ”Ogul emphasized.
In turn, the development of domestic analogues of imported drugs will reduce budget expenditures for the treatment of orphan diseases, as well as, over time, create in Russia its own scientific, technical and production base for scientific research, development and introduction of such drugs. “According to the Ministry of Health and the Ministry of Industry and Trade, a number of private pharmaceutical companies are now working to bring domestic analogues of imported drugs for rare diseases to the market. We must understand which of them are created with the help of budget funds, where the state order is used, for which specific drugs. And is it possible to consider the possibility of targeted budgetary financing of scientific developments to create a whole range of domestic drugs for the treatment of rare diseases, ”Ogul said.
Thanks for subscribing!
